このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Hikma Pharmaceuticals 過去の業績
過去 基準チェック /16
Hikma Pharmaceuticalsの収益は年間平均-14.3%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 減少しています。収益は年間0.9% 6%割合で 増加しています。 Hikma Pharmaceuticalsの自己資本利益率は8.7%であり、純利益率は6.6%です。
主要情報
-14.3%
収益成長率
-12.6%
EPS成長率
Pharmaceuticals 業界の成長 | 14.1% |
収益成長率 | 6.0% |
株主資本利益率 | 8.7% |
ネット・マージン | 6.6% |
次回の業績アップデート | 08 Aug 2024 |
最近の業績更新
Recent updates
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease
Feb 22Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?
Feb 03収支内訳
収支内訳
Hikma Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
31 Dec 23 | 2,875 | 190 | 632 | 149 |
30 Sep 23 | 2,803 | 168 | 619 | 144 |
30 Jun 23 | 2,731 | 146 | 606 | 139 |
31 Mar 23 | 2,624 | 167 | 604 | 142 |
31 Dec 22 | 2,517 | 188 | 601 | 144 |
30 Sep 22 | 2,534 | 267 | 593 | 149 |
30 Jun 22 | 2,550 | 346 | 585 | 153 |
31 Mar 22 | 2,552 | 384 | 573 | 148 |
31 Dec 21 | 2,553 | 421 | 561 | 143 |
30 Sep 21 | 2,489 | 444 | 535 | 139 |
30 Jun 21 | 2,425 | 467 | 509 | 134 |
31 Mar 21 | 2,383 | 449 | 508 | 136 |
31 Dec 20 | 2,341 | 431 | 506 | 137 |
30 Sep 20 | 2,317 | 472 | 503 | 134 |
30 Jun 20 | 2,292 | 513 | 500 | 130 |
31 Mar 20 | 2,250 | 500 | 494 | 128 |
31 Dec 19 | 2,207 | 486 | 487 | 126 |
30 Sep 19 | 2,173 | 424 | 481 | 128 |
30 Jun 19 | 2,138 | 361 | 475 | 129 |
31 Mar 19 | 2,104 | 322 | 471 | 124 |
31 Dec 18 | 2,070 | 282 | 467 | 118 |
30 Sep 18 | 2,045 | -262 | 464 | 110 |
30 Jun 18 | 2,020 | -806 | 460 | 102 |
31 Mar 18 | 1,978 | -824 | 467 | 109 |
31 Dec 17 | 1,936 | -843 | 474 | 115 |
30 Sep 17 | 1,950 | -338 | 462 | 122 |
30 Jun 17 | 1,963 | 166 | 450 | 129 |
31 Mar 17 | 1,957 | 161 | 440 | 128 |
31 Dec 16 | 1,950 | 155 | 429 | 126 |
30 Sep 16 | 1,782 | 166 | 411 | 100 |
30 Jun 16 | 1,613 | 176 | 392 | 73 |
31 Mar 16 | 1,527 | 214 | 372 | 55 |
31 Dec 15 | 1,440 | 252 | 352 | 36 |
30 Sep 15 | 1,450 | 248 | 346 | 46 |
30 Jun 15 | 1,460 | 243 | 339 | 56 |
31 Mar 15 | 1,475 | 261 | 342 | 56 |
31 Dec 14 | 1,489 | 278 | 345 | 55 |
30 Sep 14 | 1,477 | 293 | 339 | 46 |
30 Jun 14 | 1,465 | 308 | 333 | 37 |
31 Mar 14 | 1,415 | 260 | 322 | 34 |
31 Dec 13 | 1,365 | 212 | 311 | 31 |
30 Sep 13 | 1,290 | 172 | 300 | 30 |
質の高い収益: HIKには$255.0M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st December, 2023に影響を及ぼしています。
利益率の向上: HIKの現在の純利益率 (6.6%)は、昨年(7.5%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: HIKの収益は過去 5 年間で年間14.3%減少しました。
成長の加速: HIKの過去 1 年間の収益成長率 ( 1.1% ) は、5 年間の平均 ( 年間-14.3%を上回っています。
収益対業界: HIKの過去 1 年間の収益成長率 ( 1.1% ) Pharmaceuticals業界1.2%を上回りませんでした。
株主資本利益率
高いROE: HIKの 自己資本利益率 ( 8.7% ) は 低い とみなされます。